Notes / Company

Bliss GVS Pharma Ltd.

BLISSGVS BSE 506197 ISIN INE416D01022 Pharmaceuticals

Fundamentals

Market cap: ₹5,217 cr
P/E: 40.40×
ROE: 8.03%
Debt / equity: 0.07
Div yield: 0.33%
52-week range: 118.00 — 493.75

Research on Tijori Finance

Company snapshot

Bliss GVS Pharma Ltd.

Pharmaceuticals

₹5,368 cr

P/E 41.57×

Latest quarter · Mar 2026

Sales₹257 cr

Net profit₹37 cr

Op. margin+17.3%

EPS₹3.36

Strength & growth

Debt / equity0.00×

Current ratio4.02×

Sales CAGR+5.4%

EPS CAGR+4.3%

The timeline — 1 note on Bliss GVS Pharma Ltd.

July 2026

03 Jul 26 · 7:16 PM IST Lead

Lead · Mid cap

Bliss GVS picks new CEO as Anupam Rasayan era begins

Rahul Adakmol, ex-Dr. Reddy's executive, takes charge from July 2026. Current CEO Narsimha Kamath stays on as MD during transition.

Verify on exchange BSE filings for BLISSGVS NSE filings for BLISSGVS Tijori Finance company page